{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T02:16:40Z","timestamp":1775873800232,"version":"3.50.1"},"reference-count":206,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1451,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.jacc.2009.04.084","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T09:06:19Z","timestamp":1252487179000},"page":"1041-1057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Pharmacogenetics in Cardiovascular Antithrombotic Therapy"],"prefix":"10.1016","volume":"54","author":[{"given":"Francisco","family":"Mar\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Gonz\u00e1lez-Conejero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Capranzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore A.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2009.04.084_bib1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/01.ATV.0000116216.56511.39","article-title":"Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation?","volume":"24","author":"Humphries","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2009.04.084_bib2","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2002-09-2888","article-title":"Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction","volume":"101","author":"Butt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000073568","article-title":"Haemostatic gene polymorphisms in venous and arterial thrombosis","volume":"32","author":"Lane","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jacc.2009.04.084_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2350-9-66","article-title":"Investigation of 89 candidate gene variants for effects on all-cause mortality following acute coronary syndrome","volume":"9","author":"Morgan","year":"2008","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jacc.2009.04.084_bib5","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa021445","article-title":"Prediction of the risk of myocardial infarction from polymorphisms in candidate genes","volume":"347","author":"Yamada","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/01.CIR.0000051465.94572.D0","article-title":"No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age","volume":"107","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib7","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2002-09-2888","article-title":"Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction","volume":"101","author":"Butt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib8","first-page":"421","article-title":"Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction","volume":"90","author":"Rold\u00e1n","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2009.04.084_bib9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics-drug disposition, drug targets, and side effects","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(00)02126-7","article-title":"Pharmacogenetics and future drug development and delivery","volume":"355","author":"Roses","year":"2000","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.jacc.2009.04.084_bib11","doi-asserted-by":"crossref","first-page":"123S","DOI":"10.1378\/chest.08-0654","article-title":"Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"1336","author":"Guyatt","year":"2008","journal-title":"Chest"},{"issue":"Suppl 6","key":"10.1016\/j.jacc.2009.04.084_bib12","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"Suppl 6","key":"10.1016\/j.jacc.2009.04.084_bib13","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2009.04.084_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/35015728","article-title":"Pharmacogenetics and the practice of medicine","volume":"405","author":"Roses","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2009.04.084_bib15","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(00)03167-6","article-title":"Pharmacogenetics and adverse drug reactions","volume":"356","author":"Meyer","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib16","first-page":"662","article-title":"Pharmacogenetics: a molecular sophistication or a new medical tool for cardiologist","volume":"1","author":"Dirckx","year":"2000","journal-title":"Ital Heart J"},{"key":"10.1016\/j.jacc.2009.04.084_bib17","first-page":"573","article-title":"Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine","volume":"41","author":"Oscarson","year":"2003","journal-title":"Clim Chem Lab Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0009-9236(03)00088-2","article-title":"Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype","volume":"74","author":"Thijssen","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.04.084_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","article-title":"Inheritance and drug response","volume":"348","author":"Weinshilboum","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib20","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddl087","article-title":"Pharmacogenomics: from bedside to clinical practice","volume":"15","author":"Marsh","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacc.2009.04.084_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.thromres.2006.08.009","article-title":"Aspirin resistance: what, why and when?","volume":"119","author":"Shantsila","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2009.04.084_bib22","doi-asserted-by":"crossref","first-page":"27A","DOI":"10.1016\/j.amjcard.2008.11.020","article-title":"Variability in responsiveness to oral antiplatelet therapy (review)","volume":"103","author":"Angiolillo","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/eurheartj\/ehi684","article-title":"Aspirin and clopidogrel resistance: an emerging clinical entity","volume":"27","author":"Wang","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2009.04.084_bib24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1742-1241.2007.01344.x","article-title":"The genetics of aspirin resistance","volume":"61","author":"Goodman","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacc.2009.04.084_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1538-7836.2006.02234.x","article-title":"Evidence that pre-existent variability in platelet response to ADP accounts for \u201cclopidogrel resistance.\u201d","volume":"5","author":"Michelson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/bmj.39405.635498.80","article-title":"Aspirin resistance in cardiovascular disease carries a worse prognosis, but may indicate pre-existing higher risk","volume":"336","author":"Biondi-Zoccai","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2009.04.084_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1515\/CCLM.2003.039","article-title":"Platelet receptors and their role in diseases","volume":"41","author":"Clemetson","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/01.CIR.101.9.1013","article-title":"Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists","volume":"101","author":"Michelson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1055\/s-0037-1614605","article-title":"Role of the 807 C\/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function- effect in thromboembolic diseases","volume":"81","author":"Corral","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib30","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib32","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2014I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2009.04.084_bib34","doi-asserted-by":"crossref","first-page":"12387","DOI":"10.1016\/S0021-9258(19)49852-9","article-title":"Prostaglandin endoperoxide synthase","volume":"267","author":"Shimokawa","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2009.04.084_bib35","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejvs.2003.12.025","article-title":"Aspirin resistance in cardiovascular disease: a review","volume":"27","author":"Wong","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jacc.2009.04.084_bib36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib37","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1160\/TH04-02-0127","article-title":"Aspirin and coronary artery disease","volume":"92","author":"Maree","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib38","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1046\/j.1538-7836.2003.00284.x","article-title":"Aspirin resistance: definition, mechanisms and clinical read-outs","volume":"1","author":"Patrono","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/eurheartj\/ehn562","volume":"30","author":"Kuliczkowski","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2009.04.084_bib41","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.jacc.2007.07.051","article-title":"Platelet function monitoring in patients with coronary artery disease","volume":"50","author":"Gurbel","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib42","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2005.05.090","article-title":"Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation","volume":"46","author":"Tantry","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib43","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","article-title":"Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance","volume":"113","author":"Frelinger","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib44","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1161\/CIRCULATIONAHA.106.675587","article-title":"Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study","volume":"115","author":"Gurbel","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.STR.0000151362.65339.f9","article-title":"Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?","volume":"36","author":"Gonz\u00e1lez-Conejero","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2009.04.084_bib46","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib47","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","article-title":", Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators","volume":"118","author":"Eikelboom","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2009.04.084_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1015324310374","article-title":"Possible mechanisms of aspirin resistance","volume":"13","author":"Cambria-Kiely","year":"2002","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2009.04.084_bib50","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jacc.2004.01.022","article-title":"Aspirin resistance: more than just a laboratory curiosity","volume":"43","author":"Bhatt","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib51","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib52","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(05)79320-X","article-title":"Pl A2 polymorphism and efficacy of aspirin","volume":"351","author":"Cooke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib53","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0735-1097(03)00921-5","article-title":"Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GPIa\/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms","volume":"42","author":"Macchi","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib54","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2005.09.034","article-title":"Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination","volume":"47","author":"Cooke","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.thromres.2006.03.005","article-title":"Antithrombotic effects of aspirin based on Pl A1\/A2 glycoprotein IIIa polymorphism in patients with coronary disease","volume":"119","author":"Dropinski","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2009.04.084_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.athoracsur.2006.08.002","article-title":"Dose-related efficacy of aspirin after coronary surgery in patients with Pl A2 polymorphism","volume":"83","author":"Lim","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2009.04.084_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1022066305399","article-title":"Aspirin resistance and genetic polymorphisms","volume":"14","author":"Cambria-Kiely","year":"2002","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2009.04.084_bib58","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/hc4701.099787","article-title":"Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury","volume":"104","author":"Undas","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0002-9149(98)00235-5","article-title":"Pla1\/a2polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty","volume":"82","author":"Mamotte","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib60","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0140-6736(98)07257-2","article-title":"A1\/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study","volume":"353","author":"Laule","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib61","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(97)05399-3","article-title":"Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis","volume":"350","author":"Walter","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib62","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/01.CIR.99.8.1005","article-title":"Plapolymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement","volume":"99","author":"Kastrati","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0735-1097(00)00709-9","article-title":"Plapolymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement","volume":"36","author":"Kastrati","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib64","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/09537100600881412","article-title":"Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease","volume":"17","author":"Bernardo","year":"2006","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2009.04.084_bib65","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1160\/TH06-10-0583","article-title":"Lack of association between the 807 C\/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome","volume":"97","author":"Cuisset","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib66","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjcard.2005.06.039","article-title":"Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807C\/T polymorphism of the glycoprotein Ia gene","volume":"96","author":"Angiolillo","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.atherosclerosis.2006.11.009","article-title":"Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment","volume":"196","author":"Giusti","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2009.04.084_bib68","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/abbi.2000.2072","article-title":"Distinct influences of carboxyl terminal segment structure on function in the two isoforms of prostaglandin H synthase","volume":"384","author":"Guo","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jacc.2009.04.084_bib69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2003.1","article-title":"Genetic variation in cyclooxygenase 1: effects on response to aspirin","volume":"73","author":"Halushka","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.04.084_bib70","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib71","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.thromres.2007.05.017","article-title":"Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms","volume":"121","author":"Takahashi","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2009.04.084_bib72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/14622416.8.6.577","article-title":"Frequency of genetic polymorphisms of COX1, GpIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin","volume":"8","author":"Li","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jacc.2009.04.084_bib73","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.ATV.0000030340.80207.C5","article-title":"Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response","volume":"22","author":"Papafili","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2009.04.084_bib74","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2004.11.045","article-title":"Aspirin resistance and a single gene","volume":"95","author":"Jefferson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib75","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2125.2007.03044.x","article-title":"P2Y12 polymorhisms and antiplatelet effects of aspirin in patients with coronary disease","volume":"65","author":"Bierend","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2009.04.084_bib76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.0000047062.03282.A3","article-title":"Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism","volume":"107","author":"Undas","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib77","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0014-2999(98)00305-7","article-title":"Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors","volume":"351","author":"Geiger","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacc.2009.04.084_bib78","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.ATV.19.8.2007","article-title":"Specific impairment of human platelet P2YAC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel","volume":"19","author":"Geiger","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2009.04.084_bib79","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/01.CIR.100.15.1667","article-title":"Ticlopidine and clopidogrel","volume":"100","author":"Quinn","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib80","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib81","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib82","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":", Clopidogrel in Unstable angina to prevent Recurrent Events trial CURE) Investigators","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jacc.2007.10.002","article-title":"2007 focused update of the ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"51","author":"King","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib84","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2007.01.003","volume":"49","author":"Grines","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib85","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib86","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ahj.2008.06.002","article-title":"Platelet inhibitor therapy: current perspectives and emerging novel agents: introduction","volume":"156","author":"Angiolillo","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2009.04.084_bib87","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.thromres.2006.02.006","article-title":"Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel","volume":"119","author":"Lev","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2009.04.084_bib88","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2008.05.032","article-title":"Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents","volume":"52","author":"Gori","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib89","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jacc.2007.04.092","article-title":"Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism?","volume":"50","author":"Campo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib90","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","article-title":"Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently","volume":"81","author":"Farid","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.04.084_bib91","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib92","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2009.04.084_bib93","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2007.02722.x","article-title":"Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects","volume":"5","author":"Fontana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib94","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.thromres.2007.06.012","article-title":"Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness","volume":"121","author":"Fontana","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2009.04.084_bib95","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2007.11.065","article-title":"Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome","volume":"101","author":"Frere","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib96","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1253\/circj.CJ-08-0559","article-title":"Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention","volume":"73","author":"Hoshino","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2009.04.084_bib97","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/14622416.9.9.1251","article-title":"CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation","volume":"9","author":"Geisler","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jacc.2009.04.084_bib98","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib99","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1517\/14656566.9.16.2893","article-title":"Prasugrel: a novel platelet ADP P2Y12 receptor antagonist","volume":"9","author":"Angiolillo","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacc.2009.04.084_bib100","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib101","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib102","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib103","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib104","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2009.04.084_bib105","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib106","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","article-title":"Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel","volume":"26","author":"Angiolillo","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2009.04.084_bib107","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients","volume":"17","author":"Giusti","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jacc.2009.04.084_bib108","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","article-title":"Impact of P-glycoprotein on clopidogrel absorption","volume":"80","author":"Taubert","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 51","key":"10.1016\/j.jacc.2009.04.084_bib109","first-page":"A301","article-title":"Role of the C1236T rs1128503) polymorphism of the MDR-1 gene on clopidogrel responsiveness (abstr)","author":"Angiolillo","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00001721-200401000-00014","article-title":"PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation","volume":"15","author":"Angiolillo","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"Suppl 110","key":"10.1016\/j.jacc.2009.04.084_bib111","first-page":"2013","article-title":"Polymorphisms of the GP IIIa and P2Y12 receptors and modulation of antiplatelet effects of combined aspirin and clopidogrel treatment (abstr)","author":"Angiolillo","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib112","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.mbc.0000114439.81125.86","article-title":"807 C\/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment","volume":"15","author":"Angiolillo","year":"2004","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.jacc.2009.04.084_bib113","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1537-2995.1999.39499235668.x","article-title":"The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807C\/T and HPA-5 polymorphisms","volume":"39","author":"Corral","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.jacc.2009.04.084_bib114","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/hq0102.100458","article-title":"The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease","volume":"22","author":"Kunicki","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2009.04.084_bib115","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/00207230500120294","article-title":"PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy","volume":"16","author":"Smith","year":"2005","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2009.04.084_bib116","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2350-8-59","article-title":"Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease","volume":"8","author":"Cavallari","year":"2007","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jacc.2009.04.084_bib118","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1161\/01.CIR.0000106904.80795.35","article-title":"P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib119","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.thromres.2005.03.001","article-title":"Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease","volume":"116","author":"Angiolillo","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2009.04.084_bib120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.mbc.0000164429.21040.0a","article-title":"P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose","volume":"16","author":"von Beckerath","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jacc.2009.04.084_bib121","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijcard.2007.12.118","article-title":"Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene","volume":"133","author":"Staritz","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib122","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0735-1097(00)00554-4","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade in coronary artery disease","volume":"35","author":"Lincoff","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib123","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0002-8703(03)00437-X","article-title":"Optimizing glycoprotein IIb\/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention","volume":"146","author":"Januzzi","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2009.04.084_bib124","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1067\/mhj.2002.119763","article-title":"Reduced inhibition by abciximab in platelets with the PlA2 polymorphism","volume":"143","author":"Wheeler","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2009.04.084_bib125","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.V97.10.3093","article-title":"Effect of the PlA2 alloantigen on the function of beta(3)-integrins in platelets","volume":"97","author":"Bennett","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib126","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00008571-200210000-00011","article-title":"No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb\/IIIa inhibitors","volume":"12","author":"Weber","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jacc.2009.04.084_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0049-3848(02)00083-X","article-title":"Low incidence of paradoxical platelet activation by glycoprotein IIb\/IIIa inhibitors","volume":"106","author":"Weber","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2009.04.084_bib128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11239-005-2912-2","article-title":"The effect of glycoprotein IIIa PIA 1\/A2 polymorphism on the PFA-100 response to GP IIb IIIa receptor inhibitors-the importance of anticoagulants used","volume":"20","author":"Aalto-Set\u00e4l\u00e4","year":"2005","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2009.04.084_bib129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1160\/TH03-06-0341","article-title":"PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction","volume":"91","author":"Gorchakova","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib130","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","article-title":"Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization","volume":"342","author":"O'Neill","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib131","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(99)11179-6","article-title":"Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib132","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V98.12.3256","article-title":"Genetic variation in glycoprotein IIb\/IIIa (GPIIb\/IIIa) as a determinant of the responses to an oral GPIIb\/IIIa antagonist in patients with unstable coronary syndromes","volume":"98","author":"O'Connor","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib133","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00129784-200101060-00002","article-title":"Oral glycoprotein IIb\/IIIa inhibitors: why don't they work?","volume":"1","author":"Chew","year":"2001","journal-title":"Am J Cardiovasc Drugs"},{"issue":"Suppl","key":"10.1016\/j.jacc.2009.04.084_bib134","doi-asserted-by":"crossref","first-page":"311S","DOI":"10.1378\/chest.126.3_suppl.311S","article-title":"Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"1263","author":"Warkentin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2009.04.084_bib135","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1309\/BMW4M8NQBV0TKFRX","article-title":"Platelet PlA2 polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia","volume":"129","author":"Harris","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jacc.2009.04.084_bib136","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00008571-200305000-00003","article-title":"Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia","volume":"13","author":"Carlsson","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jacc.2009.04.084_bib137","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.V89.2.370","article-title":"Fc gamma RIIA H\/R 131 polymorphism, subclass-specific IgG anti-heparin\/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis","volume":"89","author":"Arepally","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib138","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood.V92.5.1526","article-title":"Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism","volume":"92","author":"Carlsson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib139","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2004-01-0058","article-title":"The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes","volume":"104","author":"Gruel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/09537100075751","article-title":"Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia","volume":"11","author":"Horsewood","year":"2000","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2009.04.084_bib141","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1538-7836.2005.01125.x","article-title":"A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype","volume":"3","author":"Ray","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib142","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jcp.45.8.704","article-title":"Factors affecting the maintenance dose of warfarin","volume":"45","author":"James","year":"1992","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jacc.2009.04.084_bib143","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1538-7836.2008.03074.x","article-title":"Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes","volume":"6","author":"Thacker","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib144","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0735-1097(03)00416-9","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"41","author":"Hirsh","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0092-8674(88)90567-3","article-title":"The molecular basis of blood coagulation","volume":"53","author":"Furie","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2009.04.084_bib146","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0304-4165(90)90072-5","article-title":"Comparison of the vitamins K1, K2 and K3 as cofactors for the hepatic vitamin K-dependent carboxylase","volume":"1034","author":"Buitenhuis","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacc.2009.04.084_bib147","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2009.04.084_bib148","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature02254","article-title":"Identification of the gene for vitamin K epoxide reductase","volume":"427","author":"Li","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2009.04.084_bib149","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx00025a009","article-title":"Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions","volume":"5","author":"Rettie","year":"1992","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jacc.2009.04.084_bib150","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1006\/bbrc.1998.9992","article-title":"Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population","volume":"254","author":"Yasar","year":"1999","journal-title":"Biochem Byophis Res Commun"},{"key":"10.1016\/j.jacc.2009.04.084_bib151","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1025052827305","article-title":"Warfarin dose adjustments based on CYP2C9 genetic polymorphisms","volume":"14","author":"Linder","year":"2002","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2009.04.084_bib152","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.084_bib153","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2009.04.084_bib154","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1614114","article-title":"Genetic modulation of oral anticoagulation with warfarin","volume":"84","author":"Margaglione","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib155","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clpt.2003.09.015","article-title":"CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy","volume":"75","author":"Peyvandi","year":"2004","journal-title":"Clin Pharmacol Ther Clin"},{"key":"10.1016\/j.jacc.2009.04.084_bib156","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.V96.5.1816","article-title":"Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment","volume":"96","author":"Taube","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib157","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00008571-200401000-00003","article-title":"The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon","volume":"14","author":"Visser","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jacc.2009.04.084_bib158","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib159","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2005-01-0341","article-title":"Cytochrome P450 2C9 CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity","volume":"106","author":"Bodin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib160","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2004-06-2111","article-title":"A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin","volume":"105","author":"D'Andrea","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib161","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clpt.2005.11.006","article-title":"Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population","volume":"79","author":"Lee","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.04.084_bib162","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/01.fpc.0000184955.08453.a8","article-title":"Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans","volume":"16","author":"Takahashi","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jacc.2009.04.084_bib163","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1160\/TH07-07-0454","article-title":"Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles","volume":"98","author":"Oldenburg","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib164","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1538-7836.2008.03116.x","article-title":"Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1","volume":"6","author":"Harrington","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib165","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib166","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1309\/1E34UAPR06PJ6HML","article-title":"Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose","volume":"129","author":"King","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jacc.2009.04.084_bib167","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin","volume":"84","author":"Gage","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.04.084_bib168","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7326\/0003-4819-130-1-199901050-00004","article-title":"Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention","volume":"130","author":"Petty","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib169","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1054\/jocn.2001.1018","article-title":"The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable","volume":"9","author":"Evans","year":"2002","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jacc.2009.04.084_bib170","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib171","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11239-007-0104-y","article-title":"Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues","volume":"25","author":"Gage","year":"2008","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2009.04.084_bib172","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2008-01-134247","article-title":"A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose","volume":"112","author":"Cooper","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib173","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib174","first-page":"127","article-title":"Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors","volume":"22","author":"D'Andrea","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.jacc.2009.04.084_bib175","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","article-title":"CYP4F2 genetic variant alters required warfarin dose","volume":"111","author":"Caldwell","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib176","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1538-7836.2007.02630.x","article-title":"The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol","volume":"5","author":"Gonz\u00e1lez-Conejero","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib177","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1160\/TH08-04-0116","article-title":"Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon","volume":"100","author":"Beinema","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib178","first-page":"753","article-title":"International Warfarin Pharmacogenetics Consortium","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib179","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1056\/NEJM200203283461302","article-title":"Reperfusion therapy in acute myocardial infarction","volume":"346","author":"Lange","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib180","doi-asserted-by":"crossref","first-page":"630S","DOI":"10.1378\/chest.08-0720","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Albers","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2009.04.084_bib181","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2009.04.084_bib182","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/oxfordjournals.eurheartj.a061905","article-title":"Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials","volume":"6","author":"Yusuf","year":"1985","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2009.04.084_bib183","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1056\/NEJM198710013171402","article-title":"Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction","volume":"317","author":"White","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.084_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9149(93)90700-M","article-title":"Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction","volume":"71","author":"Galvani","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib185","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000213","article-title":"Thrombolysis for acute ischaemic stroke","author":"Wardlaw","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2009.04.084_bib186","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1161\/01.CIR.103.23.2862","article-title":"Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1","volume":"103","author":"Armstrong","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib187","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/01.CIR.82.3.781","article-title":"Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction","volume":"82","author":"Ohman","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib188","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0735-1097(98)00139-9","article-title":"Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction","volume":"31","author":"Stewart","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib189","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/01.CIR.97.16.1632","article-title":"Thrombolysis for acute myocardial infarction","volume":"97","author":"White","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.084_bib190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/hrt.2003.019877","article-title":"Adjunctive treatment in patients treated with thrombolytic therapy","volume":"90","author":"Brouwer","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2009.04.084_bib191","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1161\/01.STR.0000098648.54429.1C","article-title":"Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene","volume":"34","author":"Montaner","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2009.04.084_bib192","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/01.mbc.0000186838.16551.ad","article-title":"Plasminogen activator inhibitor-1 4G\/5G polymorphism and efficacy of reperfusion in acute myocardial infarction","volume":"16","author":"Sibbing","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jacc.2009.04.084_bib193","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1111\/j.1538-7836.2007.02665.x","article-title":"Influence of thrombin-activable fibrinolysis inhibitor and plasmingen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients","volume":"5","author":"Fern\u00e1ndez Cadenas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib194","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0049-3848(99)00023-7","article-title":"Blood coagulation factor XIII: structure and function","volume":"94","author":"Muszbek","year":"1999","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2009.04.084_bib195","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/187152508784871990","article-title":"The involvement of blood coagulation Factor XIII in fibrinolysis and thrombosis","volume":"6","author":"Muszbek","year":"2008","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.jacc.2009.04.084_bib196","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1055\/s-0037-1614073","article-title":"Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A","volume":"84","author":"Wartiovaara","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib197","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V96.3.988","article-title":"The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure","volume":"96","author":"Ari\u00ebns","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.04.084_bib198","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0037-1614250","article-title":"Association of a common polymorphism in the factor XIII gene with myocardial infarction","volume":"79","author":"Kohler","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib199","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1055\/s-0037-1615597","article-title":"Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography","volume":"85","author":"Warner","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.04.084_bib200","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1161\/hq0202.102874","article-title":"Assessment of coronary heart disease risk by combined analysis of coagulation factors","volume":"22","author":"Aleksic","year":"2002","journal-title":"Artherioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2009.04.084_bib201","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0002-9149(03)00274-1","article-title":"Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction","volume":"91","author":"Rold\u00e1n","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib202","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1055\/s-0037-1613210","article-title":"Effect of factor XIII VAL34LEU polymorphism on thrombolytic therapy in premature myocardial infarction","volume":"88","author":"Rold\u00e1n","year":"2002","journal-title":"Thromb Haemos"},{"key":"10.1016\/j.jacc.2009.04.084_bib203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jacc.2004.09.051","article-title":"A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction","volume":"45","author":"Mar\u00edn","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.04.084_bib204","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1161\/01.STR.0000236636.39235.4f","article-title":"Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients","volume":"37","author":"Gonz\u00e1lez Conejero","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2009.04.084_bib205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neulet.2005.12.079","article-title":"ACE gene polymorphisms influence t-PA induced brain vessel reopening following ischemic stroke","volume":"398","author":"Fernandez Cadenas","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jacc.2009.04.084_bib206","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11239-008-0235-9","article-title":"Methylenetetrahydrofolate reductase (MTHFR) 6677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis","volume":"27","author":"Patti","year":"2009","journal-title":"J Thromb Thrombolysis"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109709021469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109709021469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:33:53Z","timestamp":1760013233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109709021469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":206,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0735109709021469"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2009.04.084","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics in Cardiovascular Antithrombotic Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2009.04.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}